Literature DB >> 2718699

Studies on the occurrence of ophthalmopathy in Graves' disease.

C Marcocci1, L Bartalena, F Bogazzi, M Panicucci, A Pinchera.   

Abstract

Eye disease was associated with hyperthyroidism in 202 of 221 patients with active Graves' ophthalmopathy (91.4%) and was not accompanied by thyroid hyperfunction (euthyroid Graves' disease) in the remaining 19 (8.6%). All the latter patients had some mild thyroid abnormalities (thyroid autoantibodies, negative TRH test, negative T3 suppression test, goitre). Sex distribution analysis evidenced a higher prevalence in females with a female/male ratio of 2.1 which was, however, significantly lower (P less than 0.05) than that observed in control (Graves' disease patients without overt ophthalmopathy (female/male ratio = 3.4]. Patients with euthyroid Graves' disease showed a female/male ratio of 0.7. Age distribution revealed a peak prevalence in the 5th decade of life, identical to that of Graves' disease without ophthalmopathy. A close temporal relationship between the onset of hyperthyroidism and the onset of ophthalmopathy was found, since in about 85% of the patients the first ocular manifestations occurred within +/-18 months around the onset of hyperthyroidism.

Entities:  

Mesh:

Year:  1989        PMID: 2718699     DOI: 10.1530/acta.0.1200473

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  39 in total

1.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine.

Authors:  A Barth; P Probst; H Bürgi
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

3.  The A946T polymorphism in the interferon induced helicase gene does not confer susceptibility to Graves' disease in Chinese population.

Authors:  Ze-Fei Zhao; Bin Cui; Hao-Yan Chen; Shu Wang; Imelda Li; Xue-Jiang Gu; Li Qi; Xiao-Ying Li; Guang Ning; Yong-Ju Zhao
Journal:  Endocrine       Date:  2007-11-17       Impact factor: 3.633

4.  Hyperthyroid vs hypothyroid eye disease: the same severity and activity.

Authors:  M B Kashkouli; F Pakdel; V Kiavash; I Heidari; A Heirati; S Jam
Journal:  Eye (Lond)       Date:  2011-08-05       Impact factor: 3.775

Review 5.  Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

Authors:  L Bartalena; C Marcocci; A Lai; M L Tanda
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

Review 6.  Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?

Authors:  C Marcocci; L Bartalena; A Pinchera
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

7.  Graves' hyperthyroidism and ophthalmopathy associated with pemphigus vulgaris: onset of thyroid autoimmune disease during chronic low-dose glucocorticoid therapy.

Authors:  L Bartalena; F Bogazzi; L Chiovato; M L Tanda; E Martino
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

8.  More on smoking habits and Graves' ophthalmopathy.

Authors:  L Bartalena; E Martino; C Marcocci; F Bogazzi; M Panicucci; F Velluzzi; A Loviselli; A Pinchera
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

9.  A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Authors:  Seema Kumar; Reagan Schiefer; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

Review 10.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.